{"Q": 1, "answer": "no", "rationale": "No intensifier or comparative directly modifies a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_5796", "batch_size": 200, "batch_pos": 65, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language, lacking high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_17672", "batch_size": 200, "batch_pos": 41, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_17072", "batch_size": 200, "batch_pos": 164, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18988", "batch_size": 200, "batch_pos": 140, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports actions taken but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_16504", "batch_size": 200, "batch_pos": 137, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment states manufacturers are developing or testing vaccines as a precautionary measure, which is preparedness language, not minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17072", "batch_size": 200, "batch_pos": 105, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment states executives are developing or testing vaccines, which is a factual statement, not a bare negation or explicit calming cue.", "method": "llm_batch", "batch_id": "batch_7_2772", "batch_size": 200, "batch_pos": 84, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes ongoing/future actions as capability/preparedness ('are already developing or about to test sample human vaccines') without explicit reassurance.", "method": "llm_batch", "batch_id": "batch_8_17088", "batch_size": 200, "batch_pos": 127, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
